U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07493135) titled 'A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma' on March 19.
Brief Summary: This is an investigator-initiated, single-center, early-phase clinical study comprising dose escalation and dose expansion phases, designed to evaluate the safety and efficacy of IMV102 in subjects with relapsed/refractory multiple myeloma (RRMM). Eligible subjects will receive an infusion of IMV102 injection. Blood and urine samples will be collected before and after infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety assessments.
Tumor response will be evaluated according to the International Myeloma Working...